GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Upstream Bio Inc
Shares of Upstream Bio, a biotech focused on treating inflammatory diseases, reflect the potential of its lead drug. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Pharma immune
Upstream Bio (UPB) is a clinical-stage biotech company focused on developing novel treatments for allergic and inflammatory diseases related to the immune system. We classify it in the Pharmaceuticals/Immunology segment. The chart below reflects the overall performance of this cutting-edge biotech sector.
Broad Market Index - GURU.Markets
Upstream Bio is a biopharmaceutical company developing drugs to treat inflammatory diseases caused by allergies. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
UPB - Daily change in the company's share price Upstream Bio Inc
For Upstream Bio, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects the company's sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models at System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Pharma immune
Upstream Bio Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with UPB's performance, which depends on clinical trial results, helps to assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Upstream Bio is a biopharmaceutical company specializing in drugs for the treatment of immune diseases. Immunology is a cutting-edge but highly volatile segment of biotechnology. The chart below shows average daily fluctuations in this area, allowing you to assess Upstream's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Upstream Bio Inc
Upstream Bio is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma immune
Upstream Bio, a private biotech company, develops drugs to treat inflammatory diseases. Its growth depends on success in clinical trials. Its valuation reflects investor confidence in its scientific platform, potentially outperforming the overall pharmaceutical sector, but with higher risks.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Upstream Bio is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where data releases are the key events.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Upstream Bio Inc
As a biopharmaceutical company, Upstream Bio's value will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news about the progress of clinical trials of its drugs for the treatment of allergic and inflammatory diseases, which will determine its future.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Upstream Bio is a clinical-stage biotech company focused on developing therapies for allergic and inflammatory diseases related to the immune system. Its value reflects investor expectations for future breakthroughs. The chart below reflects the overall sentiment in the immunopharmaceutical sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Upstream Bio Inc. is a clinical-stage biotech company focused on immune diseases. Its stock moves solely on research progress news. The company's performance is completely disconnected from market cycles and represents a binary bet on the success or failure of its research.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Upstream Bio Inc
Shares of Upstream Bio, a clinical-stage biotech, exhibit extreme volatility on a weekly basis. Any news, even minor, about the progress of its asthma drug trials can trigger sharp and dramatic price movements, reflecting the binary outcome.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Upstream Bio shares, like the entire early-stage biotech sector, move in tandem with investor sentiment and scientific breakthroughs. The success or failure of one company can impact the entire niche. The chart shows how the company's shares react to this general "noise."
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biotech companies like Upstream Bio often live in their own world, isolated from broader market fluctuations. Their stocks' fates are determined by clinical trial news, not inflation reports. The chart will show how often their stocks move against the broader market tide.
Market capitalization of the company, segment and market as a whole
UPB - Market capitalization of the company Upstream Bio Inc
Upstream Bio's market capitalization chart visualizes investor hopes for a new approach to treating asthma and other inflammatory diseases. It reflects the estimated potential of its lead antibody. Its speculative dynamics are a classic story for a clinical-stage biotech company, where value is determined by future research results.
UPB - Share of the company's market capitalization Upstream Bio Inc within the market segment - Pharma immune
Upstream Bio is a biotech company developing a new antibody drug for the treatment of allergic and inflammatory diseases, including asthma. Its market share is based on the potential of this candidate. The chart shows how the market perceives its chances of creating a blockbuster drug with a convenient dosing regimen.
Market capitalization of the market segment - Pharma immune
Upstream Bio is a biopharmaceutical company developing treatments for allergic and inflammatory diseases. The chart below shows the overall market capitalization of the immunopharmaceuticals sector. Its growth reflects the enormous hopes for developing drugs that can control an overactive immune system.
Market capitalization of all companies included in a broad market index - GURU.Markets
The biotech companies featured in the chart are exploring new approaches to treating inflammatory diseases. Upstream Bio is developing an antibody to treat asthma and other allergic conditions. Its capitalization is a risky bet that its drug will offer a superior solution to existing therapies.
Book value capitalization of the company, segment and market as a whole
UPB - Book value capitalization of the company Upstream Bio Inc
Upstream Bio's chart represents capital invested in the fight against inflammatory diseases. Currently in clinical trials, the company is using its financial assets, reflected in the chart, to develop a new antibody targeting asthma and other allergic conditions.
UPB - Share of the company's book capitalization Upstream Bio Inc within the market segment - Pharma immune
Upstream Bio, a clinical-stage biotech company, focuses on immunology. Its share of the sector's assets is minimal, consisting of R&D assets. At this stage, its value lies in the potential of its lead drug candidate, not in its physical assets.
Market segment balance sheet capitalization - Pharma immune
Upstream Bio is a biotechnology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Upstream focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Upstream Bio is a biotech company developing drugs to treat allergic and inflammatory diseases. Its book value is derived from the capital it is using to conduct clinical trials for its lead antibody.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Upstream Bio Inc
Upstream Bio is a biotech company. Its market capitalization is a premium to its cash flow, reflecting investors' bet on the success of its clinical program in the treatment of allergic and inflammatory diseases.
Market to book capitalization ratio in a market segment - Pharma immune
Upstream Bio is a clinical-stage biotech company developing therapies for allergic and inflammatory diseases. Its value is based almost entirely on the potential of its lead drug. The chart shows the high market valuation of its science compared to its virtually nonexistent tangible assets.
Market to book capitalization ratio for the market as a whole
Upstream Bio is a biotech company developing drugs to treat allergic and inflammatory diseases. Compared to average market valuations, as shown in this chart, its high premium is based solely on the scientific potential of its lead candidate and investors' confidence in its future success.
Debts of the company, segment and market as a whole
UPB - Company debts Upstream Bio Inc
Upstream Bio is a clinical-stage biotech company developing therapies for allergic and inflammatory diseases. Without any products on the market, the company is entirely dependent on external funding to conduct expensive clinical trials. This chart illustrates how the company manages its financial resources to advance its lead candidate.
Market segment debts - Pharma immune
Upstream Bio is an early-stage biopharmaceutical company focused on treating allergic and inflammatory diseases. The company has no products on the market, and its survival depends on its ability to raise equity capital to fund R&D. This chart reflects its current financial position.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Upstream Bio Inc
Upstream Bio is an early-stage biotech company developing drugs for the treatment of allergic and inflammatory diseases. This chart shows its financial structure. For a company with no products on the market and no revenue, any debt is a significant risk, and its survival depends entirely on its ability to raise equity capital.
Market segment debt to market segment book capitalization - Pharma immune
Upstream Bio is a clinical-stage biotech company developing treatments for allergic and inflammatory diseases. The path to drug approval requires significant investment. This chart shows the overall debt burden in the pharmaceutical industry, providing context for understanding how the company finances its expensive research and development.
Debt to book value of all companies in the market
Upstream Bio Inc. is an early-stage biotech company focused on treating allergic and inflammatory diseases. With no products on the market, it is entirely dependent on investor funding. This chart clearly demonstrates that the debt market is closed to such companies, and their survival depends solely on faith in their scientific potential.
P/E of the company, segment and market as a whole
P/E - Upstream Bio Inc
For Upstream Bio, a clinical-stage biopharmaceutical company, the P/E ratio is irrelevant. The company has no profit, and its valuation on this chart is arbitrary. Its real value lies in the potential of its scientific developments in treating immune diseases and investors' faith in their success.
P/E of the market segment - Pharma immune
Upstream Bio is a clinical-stage biotechnology company focused on developing novel treatments for allergic and inflammatory diseases. This chart shows the average valuation for the sector, providing investors with context for assessing the scientific potential and risks associated with Upstream Bio's portfolio.
P/E of the market as a whole
Upstream Bio (privately held, ticker symbol UPB may be misleading) is a biotech developing drugs to treat allergic and inflammatory diseases. Its valuation is a pure bet on the success of its clinical programs. Overall market sentiment, reflected in this chart, is completely irrelevant. Its fate depends on research data, not GDP.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Upstream Bio Inc
Upstream Bio is a clinical-stage biotech company developing drugs for the treatment of allergic and inflammatory diseases, particularly asthma. Its value is based on the future potential of its lead candidate. This chart reflects investors' confidence in the success of clinical trials and the commercial potential of the new drug.
%20P%2FE%20Upstream%20Bio%20Inc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Upstream-Bio-Inc&v=1772546895956 "Chart of the company's future (projected) P/E Upstream Bio Inc")
Future (projected) P/E of the market segment - Pharma immune
Upstream Bio is a clinical-stage biotech company developing monoclonal antibody-based therapies for inflammation-related diseases. The chart reflects average profitability expectations for the biotech sector. UPB's position relative to this benchmark reflects investors' bet on the potential of their lead candidate for the treatment of asthma and other allergies.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772546895979 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Upstream Bio Inc. is an early-stage biotech company working in the field of immunology. Its value is almost entirely based on expectations of future success. This chart, showing investors' overall risk appetite, indicates how easily companies like Upstream Bio can raise capital for research that could take many years.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772546896072 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Upstream Bio Inc
Upstream Bio is a clinical-stage biotech company focused on treating allergic and inflammatory diseases. Its current financial schedule consists of R&D and clinical trial expenses for its lead candidate. Potential profit is entirely dependent on the successful commercialization of the drug.
Profit of companies in the market segment - Pharma immune
Upstream Bio is a clinical-stage biotech company developing drugs to treat inflammation-related diseases, such as asthma. Its future depends on the success of its clinical trials. This chart shows the overall profitability of the immunopharmaceutical industry. It is an indicator of the industry's success in developing and bringing new generations of drugs to market.
Overall market profit
Upstream Bio is a clinical-stage biotech company developing therapies for allergic and inflammatory diseases. Its current valuation is determined not by economic cycles, but by the potential of its scientific developments. However, the overall market situation, reflected in this chart, affects the availability of funding necessary for costly trials.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Upstream Bio Inc
Upstream Bio is a clinical-stage biotechnology company developing therapies for allergic and inflammatory diseases, particularly asthma. Future revenue is entirely dependent on the success of its developments. This chart reflects analysts' speculative expectations regarding the scientific and commercial potential of its lead drug candidate.
%20profit%20of%20the%20company%20Upstream%20Bio%20Inc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Upstream-Bio-Inc&v=1772546896293 "Graph of future (projected) profit of the company Upstream Bio Inc")
Future (predicted) profit of companies in the market segment - Pharma immune
Upstream Bio is a clinical-stage biotech company developing monoclonal antibody-based therapies for allergic and inflammatory diseases such as asthma. Its future depends on the success of its trials. This chart reflects profitability projections for the entire biotech sector, providing context for assessing Upstream Bio's potential and risks in this complex field.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772546896347 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Upstream Bio is an early-stage biotech company focused on treating allergic and inflammatory diseases. Its value and prospects are determined entirely by scientific developments and clinical trial results. The macroeconomic metrics presented in this chart are irrelevant at this stage.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772546896389 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Upstream Bio Inc
Upstream Bio is a clinical-stage biotech company focused on treating allergic and inflammatory diseases. Without sales revenue, this chart represents pure expectations. Its high value is based on the potential of its lead drug candidate and the size of the addressable market it could capture if successful.
P/S market segment - Pharma immune
Upstream Bio is a clinical-stage biotech developing drugs to treat inflammation-related diseases, such as asthma. Future revenue is dependent on the success of its lead candidate. This pharma chart compares investor expectations for Upstream Bio's potential with those of other immunology companies.
P/S of the market as a whole
Upstream Bio is a clinical-stage biotech developing drugs to treat inflammation-related diseases, such as asthma. Its valuation is based on the potential of its pipeline drugs. This market revenue valuation chart helps understand investor expectations for companies whose products could revolutionize the treatment of common diseases.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Upstream Bio Inc
Upstream Bio is a clinical-stage biotech company focused on developing therapies for allergic and inflammatory diseases, particularly asthma. This chart shows how investors assess the future commercial potential of its lead drug candidate, betting on the success of clinical trials.
%20P%2FS%20Upstream%20Bio%20Inc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Upstream-Bio-Inc&v=1772546896703 "The graph of the company's future (projected) P/S Upstream Bio Inc")
Future (projected) P/S of the market segment - Pharma immune
Upstream Bio is a clinical-stage biotech company developing a new drug for the treatment of severe asthma and other inflammatory diseases. The company's valuation is based on investors' belief in the potential of its lead candidate, which may offer a more convenient dosing regimen than existing treatments in this multi-billion-dollar market.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772546896764 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Upstream Bio is a clinical-stage biotech company focused on treating allergic and inflammatory diseases. Its valuation is based on the potential of its future drugs. Given the overall revenue growth picture illustrated by the chart, Upstream Bio represents a venture capital investment in the future of medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772546896810 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Upstream Bio Inc
Upstream Bio is a clinical-stage biotech company focused on treating inflammatory diseases. The company currently has no commercial products and, therefore, no revenue from sales. Any revenue reflected in the chart likely comes from funding through partnerships.
Sales of companies in the market segment - Pharma immune
Upstream Bio (UPB) is a clinical-stage biotech company focused on developing treatments for inflammatory and allergic diseases. Its lead candidate is targeting asthma. This chart shows revenue in the immunology pharmaceutical sector, where Upstream Bio aims to create best-in-class treatments for millions of patients worldwide.
Overall market sales
Upstream Bio is a clinical-stage biotech company developing treatments for allergic and inflammatory diseases. Its future depends on successful research and its ability to attract capital. This chart, reflecting the overall state of the economy and stock markets, influences the investment climate for the biotech sector and the availability of financing.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Upstream Bio Inc
Upstream Bio is a clinical-stage biotech company focused on developing therapies for allergic and inflammatory diseases, particularly asthma. Its future revenue is entirely dependent on the success of clinical trials. This chart reflects analyst forecasts, which are essentially estimates of the likelihood of commercialization of their lead drug candidate.
%20sales%20of%20the%20company%20Upstream%20Bio%20Inc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Upstream-Bio-Inc&v=1772546897079 "Schedule of future (projected) sales of the company Upstream Bio Inc")
Future (projected) sales of companies in the market segment - Pharma immune
Upstream Bio is a biopharmaceutical company developing drugs to treat allergic and inflammatory diseases. The forecast on this chart reflects the potential future revenue of their lead drug candidate. This is an analyst's view on the commercial prospects of their approach to treating immune-related diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772546897102 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Upstream Bio is a clinical-stage biotech company specializing in the treatment of allergic and inflammatory diseases. Its valuation is based on the potential of its lead drug candidate. This chart, reflecting overall market sentiment, impacts the availability of capital to fund lengthy and expensive clinical trials.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772546897174 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Upstream Bio Inc
Upstream Bio is a clinical-stage biotech company developing a new drug for the treatment of asthma and other inflammatory diseases. Its financial performance at this stage reflects significant investment in research. The chart shows its current profitability, which represents an investment in a potential blockbuster with the potential to generate significant profits in the future.
Market segment marginality - Pharma immune
Upstream Bio is a clinical-stage biotech focused on treating allergic and inflammatory diseases. This chart reflects its operating expenses. As with other biotechs without revenue, the dynamics of this metric are important for assessing the effectiveness of capital management during drug development.
Market marginality as a whole
Upstream Bio is a clinical-stage biotechnology company developing therapies for allergic and inflammatory diseases. Its future depends entirely on successful trials and capital raising. This gross profitability chart reflects the investment climate. The favorable economic environment facilitates raising funds for long-term R&D projects.
Employees in the company, segment and market as a whole
Number of employees in the company Upstream Bio Inc
Upstream Bio is a clinical-stage biotech company focused on treating allergic and inflammatory diseases. Its small but growing team consists of highly qualified scientists and physicians. Growth on this chart indicates progress in clinical trials of its lead drug candidate.
Share of the company's employees Upstream Bio Inc within the market segment - Pharma immune
Upstream Bio is a clinical-stage biotech company focused on treating inflammation-related diseases. At this stage, its core asset is its team of scientists and clinicians advancing its lead drug candidate through clinical trials. This chart reflects the scale of human investment in research to address serious medical problems.
Number of employees in the market segment - Pharma immune
Upstream Bio is a clinical-stage biotechnology company focused on treating allergic and inflammatory diseases. The employment dynamics in the immunopharmacology sector, seen here, demonstrate how competitive and rapidly evolving this field is. For Upstream Bio, this means working in an environment where scientific breakthroughs are constantly occurring, requiring speed and focus.
Number of employees in the market as a whole
Upstream Bio is a clinical-stage biotech company specializing in inflammatory diseases. Its team of scientists is focused on advancing its pipeline of drugs. Hiring is driven by research milestones and funding, rather than the overall business cycle, as the company seeks talent from the broader labor market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Upstream Bio Inc (UPB)
Upstream Bio is a biotech company developing a drug to treat allergic and inflammatory diseases such as asthma. Its entire capital comes from the potential of a single drug. This metric demonstrates the enormous value the market places on this asset, developed by a small team of expert scientists.
%20of%20the%20company%20Upstream%20Bio%20Inc%20(UPB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Upstream-Bio-Inc-UPB&v=1772546897611 "Chart of market capitalization per employee (in thousands of dollars) of the company Upstream Bio Inc (UPB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Upstream Bio is a clinical-stage biotech company developing drugs to treat allergic and inflammatory diseases. Its market capitalization is a bet on the success of future research. The chart shows the enormous potential value the market places on the work of each of the company's scientists.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772546897756 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Upstream Bio is a clinical-stage biotech company developing drugs for the treatment of allergic and inflammatory diseases. The chart reflects its scientific potential. The company's entire value is derived from the hope for its future drugs. This indicator demonstrates the value the market places on the research of each scientist on the team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772546897850 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Upstream Bio Inc (UPB)
Upstream Bio is a clinical-stage biotech developing therapies for asthma and other inflammatory diseases. Like other R&D companies, its profits are negative. This chart shows the investment (loss) per employee spent on bringing their lead drug candidate to market.
%20Chart%20Upstream%20Bio%20Inc%20(UPB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Upstream-Bio-Inc-UPB&v=1772546897958 "Company Profit Per Employee (in thousands of dollars) Chart Upstream Bio Inc (UPB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Upstream Bio is a clinical-stage biotech company developing drugs for the treatment of allergic and inflammatory diseases (such as asthma). Like other R&D companies, this metric is negative (loss per employee), reflecting the high cost of conducting clinical trials.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772546897995 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Upstream Bio is a clinical-stage biotech company developing therapies (antibodies) for the treatment of allergic and inflammatory diseases, such as asthma. It's an R&D business. There's no profit. This chart is important to understand that in immunology biotech, employees are a cost center, creating intellectual property that (potentially) will become a blockbuster.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772546898112 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Upstream Bio Inc (UPB)
Upstream Bio is a biotech company focused on treating allergic and inflammatory diseases. Being in clinical development, it has no commercial revenue yet. This graph will show zero values, which is typical for R&D companies whose value lies in the potential of their scientific discoveries.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Upstream-Bio-Inc-UPB&v=1772546898187 "Sales chart per company employee Upstream Bio Inc (UPB)")
Sales per employee in the market segment - Pharma immune
Upstream Bio (UPB) is a clinical-stage biotech company focused on developing treatments for inflammatory and immunological diseases. This chart shows the average revenue per employee in the sector. It's important for assessing the efficiency of capital utilization and staffing compared to other biotech companies.
Sales per employee for the market as a whole
Upstream Bio (UPB) is a clinical-stage biotech company focused on developing therapies for allergic and inflammatory diseases, including asthma. Like other companies in this phase, Upstream Bio likely has no revenue. This near-zero figure reflects ongoing investment in the research staff working on the development of a future blockbuster.
Short shares by company, segment and market as a whole
Shares shorted by company Upstream Bio Inc (UPB)
Upstream Bio (UPB) is a clinical-stage biotech developing treatments for allergic and inflammatory diseases, particularly asthma. This chart shows bearish sentiment. The high level of short positions reflects significant risks: investors may doubt that UPB's drug will be able to compete with existing blockbusters in the asthma treatment market. (343)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Upstream-Bio-Inc-UPB&v=1772546898395 "Short Shares Chart for the Company Upstream Bio Inc (UPB)")
Shares shorted by market segment - Pharma immune
Upstream Bio is a clinical-stage biotech company developing therapies (antibodies) for the treatment of asthma and other inflammatory diseases. This chart reflects the overall sentiment in the sector, reflecting investor skepticism toward biotech companies operating in the highly competitive field of immunology.
Shares shorted by the overall market
Upstream Bio (UPB) is a clinical-stage biotech focused on treating allergic and inflammatory diseases. Like any biotech without revenue, its value is based on the hope for a future drug. This chart measures the level of disbelief in this drug. "Bears" are betting that clinical trials will fail or that the market for this drug will be smaller than expected.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Upstream Bio Inc (UPB)
Upstream Bio is a clinical-stage biotech developing treatments for allergic and inflammatory diseases (such as asthma). This chart measures pure hope. It shows when the stock is overbought on expectations of positive trial data or oversold amid delays or a general cooling in the sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Upstream-Bio-Inc-UPB&v=1772546898547 "RSI 14 indicator chart for the company's stock Upstream Bio Inc (UPB)")
RSI 14 Market Segment - Pharma immune
Upstream Bio is a clinical-stage biotech company focused on developing treatments for allergic and inflammatory diseases, particularly chronic urticaria and asthma. This chart reflects the overall sentiment in the biotech sector and helps assess how the market views this speculative industry.
RSI 14 for the overall market
Upstream Bio (UPB) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast UPB (Upstream Bio Inc)
Upstream Bio (UPB) is a clinical-stage biotech developing treatments for allergic and inflammatory diseases, such as asthma. This chart shows the average 12-month forecast. It reflects analysts' confidence in the company's scientific platform and the potential success of its clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-UPB-Upstream-Bio-Inc&v=1772546898757 "A chart showing analyst consensus forecasts for the expected stock price. UPB (Upstream Bio Inc)")
The difference between the consensus estimate and the actual stock price UPB (Upstream Bio Inc)
Upstream Bio is a biotech company developing drugs to treat allergic and inflammatory diseases, primarily severe asthma. This chart measures the gap between the current price and the consensus target price. It shows how confident experts are in the clinical and commercial potential of their lead candidate.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-UPB-Upstream-Bio-Inc&v=1772546898829 "A chart showing the difference between the consensus forecast and the actual stock price. UPB (Upstream Bio Inc)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Upstream Bio is a clinical-stage biotech company developing antibodies for the treatment of severe allergic and inflammatory diseases (asthma, CRS). This chart shows analysts' overall expectations for the immunopharma sector. It reflects whether experts believe in the success of new approaches to treating chronic inflammation.
Analysts' consensus forecast for the overall market share price
Upstream Bio is a clinical-stage biotech company specializing in the treatment of allergies and inflammatory diseases (e.g., asthma). This chart shows overall market sentiment. For Upstream Bio, as an R&D company, it's important to understand how overall risk appetite (analyst sentiment) impacts their ability to fund expensive clinical trials. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Upstream Bio Inc
Upstream Bio (UPB) is a clinical-stage biotech focused on developing drugs for the treatment of allergic and inflammatory diseases (asthma, urticaria). This chart represents pure R&D value. Its valuation is not tied to current revenue but reflects investors' faith in their scientific platform and the potential of their lead drug candidate.
AKIMA Market Segment Index - Pharma immune
Upstream Bio (UPB) is a clinical-stage biotech focused on immunology; the company is developing a novel, long-acting antibody for the treatment of asthma and inflammatory diseases. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does UPB's R&D focus on asthma differentiate it from the average pharma company?
The AKIM Index for the overall market
Upstream Bio is a biotech company developing therapies for inflammatory diseases (such as asthma). Focusing on the TSLP receptor, this chart, which reflects the market average, provides a macro backdrop. It helps assess how this clinical-stage research story compares to the overall economic trends affecting the immunology sector.
